Windtree Therapeutics Inc has a consensus price target of $1, established from looking at the 1 latest analyst ratings. The last 1 analyst ratings were released from HC Wainwright & Co. on January 3, 2024. With an average price target of $1 between HC Wainwright & Co., there's an implied -71.01% downside for Windtree Therapeutics Inc from these 1 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
01/03/2024 | Buy Now | -71.01% | HC Wainwright & Co. | Vernon Bernardino | → $18 | Initiates | → Neutral | Get Alert |
The latest price target for Windtree Therapeutics (NASDAQ: WINT) was reported by HC Wainwright & Co. on January 3, 2024. The analyst firm set a price target for $1.00 expecting WINT to fall to within 12 months (a possible -71.01% downside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Windtree Therapeutics (NASDAQ: WINT) was provided by HC Wainwright & Co., and Windtree Therapeutics initiated their neutral rating.
There is no last upgrade for Windtree Therapeutics.
There is no last downgrade for Windtree Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Windtree Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Windtree Therapeutics was filed on January 3, 2024 so you should expect the next rating to be made available sometime around January 3, 2025.
While ratings are subjective and will change, the latest Windtree Therapeutics (WINT) rating was a initiated with a price target of $0.00 to $1.00. The current price Windtree Therapeutics (WINT) is trading at is $3.45, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.